Bar Harbor Trust Services lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 3.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,161 shares of the company’s stock after selling 422 shares during the quarter. Bar Harbor Trust Services’ holdings in Merck & Co., Inc. were worth $1,024,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Cowen Prime Advisors LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $31,000. PARK CIRCLE Co lifted its position in Merck & Co., Inc. by 100.0% in the 2nd quarter. PARK CIRCLE Co now owns 400 shares of the company’s stock worth $31,000 after buying an additional 200 shares during the last quarter. AlphaMark Advisors LLC bought a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $39,000. Lake Point Wealth Management bought a new stake in Merck & Co., Inc. in the 2nd quarter worth approximately $40,000. Finally, ShoreHaven Wealth Partners LLC lifted its position in Merck & Co., Inc. by 55.5% in the 1st quarter. ShoreHaven Wealth Partners LLC now owns 619 shares of the company’s stock worth $48,000 after buying an additional 221 shares during the last quarter. Institutional investors own 71.83% of the company’s stock.
MRK stock traded up $0.21 during midday trading on Tuesday, hitting $72.14. The stock had a trading volume of 228,335 shares, compared to its average volume of 11,461,917. The firm has a market cap of $182.61 billion, a price-to-earnings ratio of 32.84, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The business has a 50-day moving average of $76.21 and a two-hundred day moving average of $76.57. Merck & Co., Inc. has a 52-week low of $70.89 and a 52-week high of $85.60. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.31 and a quick ratio of 1.06.
The company also recently announced a quarterly dividend, which will be paid on Thursday, October 7th. Shareholders of record on Wednesday, September 15th will be issued a $0.65 dividend. This represents a $2.60 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date is Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is 43.77%.
A number of research firms recently weighed in on MRK. Morgan Stanley downgraded Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $90.00 to $85.00 in a research report on Tuesday, September 7th. SVB Leerink boosted their target price on Merck & Co., Inc. from $99.00 to $101.00 and gave the stock an “outperform” rating in a research report on Friday, July 30th. Zacks Investment Research upgraded Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 price objective for the company in a research report on Tuesday, August 24th. JPMorgan Chase & Co. lowered their price objective on Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Wednesday, June 9th. Finally, Truist Securities began coverage on Merck & Co., Inc. in a research report on Tuesday, July 27th. They issued a “buy” rating and a $76.79 price objective for the company. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $91.09.
Merck & Co., Inc. Company Profile
Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Recommended Story: Basic Economics creates winners and losers
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.